These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Brinzolamide 1%/timolol 0.5%: safety and efficacy of a new fixed-combination IOP-lowering product for glaucoma.
    Author: Januleviciene I.
    Journal: Curr Med Res Opin; 2010 Nov; 26(11):2575-8. PubMed ID: 20868340.
    Abstract:
    OBJECTIVE: To provide a commentary on recent studies with the new IOP-lowering fixed-combination product brinzolamide 1%/timolol 0.5%. METHODS: Medline was searched for brinzolamide/timolol fixed-combination clinical literature (up to May 18, 2010) and the current comprehensive brinzolamide/timolol literature was reviewed. RESULTS: Compared with another carbonic anhydrase inhibitor-containing product, dorzolamide 2%/timolol 0.5%, brinzolamide/timolol has similar IOP-lowering efficacy. Brinzolamide/timolol also produces superior comfort ratings as assessed by patients who have tried both drugs - this may be explained by the more physiologic pH of brinzolamide/timolol. A recent study reported that brinzolamide/timolol was preferred over dorzolamide/timolol at a ratio of nearly 4:1 among those expressing a preference. CONCLUSION: These results demonstrate that brinzolamide/timolol is equally effective and more comfortable than dorzolamide/timolol, a fact that may positively impact patient adherence, leading to an increased likelihood of reaching target IOP goals.
    [Abstract] [Full Text] [Related] [New Search]